Recognizing February 16, 2011, as Susan G.Komen for the Cure Advocacy Day.
Impact
The bill is primarily symbolic in nature, aiming to raise awareness about breast cancer and honor the work being done at the community level by Susan G. Komen for the Cure. By designating a specific day for advocacy, it seeks to mobilize citizens, communities, and lawmakers to focus their attention on breast cancer, its prevention, and the importance of research. Additionally, it highlights the ongoing need for funding and support for breast cancer research and patient care programs, which could influence future legislative efforts related to healthcare funding and public health initiatives.
Summary
HR383 is a resolution recognizing February 16, 2011, as Susan G. Komen for the Cure Advocacy Day in Texas. This resolution acknowledges the significant efforts made by the Susan G. Komen for the Cure organization, which has established a grassroots network dedicated to the fight against breast cancer. Founded in 1982 by Nancy G. Brinker, this organization has since become a leading advocate for breast health awareness, research funding, and support for those affected by breast cancer. The resolution celebrates the contributions of the organization, which has invested nearly $2 billion in the fight against breast cancer, significantly impacting early detection and survivorship rates.
Sentiment
Sentiment surrounding HR383 is overwhelmingly positive, as it aligns with the widely supported cause of fighting breast cancer. Legislators and community members alike recognize the importance of awareness and advocacy in combating this disease that affects so many. The discussions likely reflect a shared commitment to improving breast cancer outcomes, supporting survivors, and investing in further research efforts. By proclaiming a day dedicated to advocacy, the resolution fosters a sense of community and calls for collective action.
Contention
While HR383 largely celebrates the efforts of Susan G. Komen for the Cure, it is important to recognize that discussions around healthcare funding and research can bring about differing opinions. Some individuals may argue for the need to diversify funding sources for cancer research beyond a single organization, while others might highlight the importance of sustaining support for established entities like Komen. Consequently, while there may not be significant contention directly associated with this resolution, it exists within a broader dialogue about healthcare equity, access to treatment, and the effectiveness of various advocacy strategies.